CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating activities
Net (loss) income	$ (4,627)	$ 736
Adjustments to reconcile net income (loss) to cash provided by operating activities:
Depreciation	6,281	7,331
Amortization of intangible assets	1,794	1,390
Provision for bad debts	129	53
Stock-based compensation	540	634
Amortization of loan fees	185	43
Loss on extinguishment of debt	151	43
Loss on write-off of financing costs	273	0
Gain on disposal of discontinued operations	(350)	(6,161)
Gain on sale of Telerhythmics	0	(19)
Gain on sale of assets	(136)	(46)
Unrealized (gain) loss on equity securities	(62)	62
Goodwill impairment	0	476
Goodwill tax adjustment	(265)	0
Deferred income taxes	(98)	(133)
Changes in operating assets and liabilities:
Accounts receivable	(3,325)	3,026
Inventories	(30)	(12)
Other assets	(317)	686
Accounts payable	(463)	25
Accrued compensation	211	(1,645)
Deferred revenue	155	(749)
Operating lease liabilities	(37)	0
Other liabilities	391	(676)
Net cash provided by operating activities	400	5,064
Investing activities
Purchases of property and equipment	(1,512)	(2,163)
Purchase of real estate from related and third parties	(5,180)	0
Proceeds from sale of discontinued operations	0	6,844
Proceeds from sale of property and equipment	1,734	2,095
Sale (purchases) of equity securities	140
Sale (purchases) of equity securities		(13)
Payments to acquire interest in joint ventures	(1,000)	0
Net cash (used in) provided by investing activities	(5,818)	8,685
Financing activities
Proceeds from borrowings	98,541	33,347
Repayment of debt	(91,203)	(43,347)
Issuances of preferred stock	3,000	0
Loan issuance costs and extinguishment costs	(662)	24
Dividends paid	0	(3,321)
Issuances of common stock	0	26
Repayment of Gerber acquisition loan	(3,000)	0
Fees payable on issuance of preferred stock	(150)	0
Deferred financing costs	27	0
Taxes paid related to net share settlement of equity awards	(24)	(74)
Repayment of obligations under finance leases	(863)	(811)
Net cash provided by (used in) financing activities	5,666	(14,156)
Net increase (decrease) in cash, cash equivalents, and restricted cash	248	(407)
Cash, cash equivalents, and restricted cash at beginning of year	1,813	2,220
Cash, cash equivalents, and restricted cash at end of year	2,061	1,813
Supplemental Information
Cash paid during the period for interest	1,083	702
Cash paid during the period for income taxes	102	52
Telerhythmics
Investing activities
Proceeds from sale of discontinued operations	$ 0	$ 1,922